Nektar Therapeutics (NKTR) News Today

Nektar Therapeutics (NASDAQ: NKTR) is under pressure as investors appear to be focusing on concerns about the commercial outlook for its lead drug candidate, rezpegaldesleukin (REZPEG), rather than its encouraging long-term clinical data. The stock’s elevated trading volume indicates heightened investor reaction and volatility.

• Positive Sentiment: New Phase 2b data showed durable responses in alopecia areata: 75% of responders maintained a SALT score of 20 or lower four months after treatment ended, while 63% maintained that response after six months. Hair regrowth also continued after treatment, with 19% of patients reaching a SALT score of 10 or lower. New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement
• Positive Sentiment: Nektar has expanded its Phase 3 ZENITH atopic dermatitis program into treatment-experienced patients and expects to begin the Phase 3 ZENITH alopecia areata study in early 2027, creating additional clinical catalysts.
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $185 price target, implying substantial upside based on its long-term valuation assumptions.
• Neutral Sentiment: Management and analysts discussed the REZPEG data and development strategy, while additional biomarker results indicated early molecular responses across immune pathways involved in atopic dermatitis.
• Negative Sentiment: The market reaction suggests investors view the new data as insufficient to remove concerns about REZPEG’s commercial opportunity, competitive positioning, or the time and risk involved in reaching approval. Nektar Therapeutics Downgrade to Hold
• Negative Sentiment: An analyst downgrade to Hold and reports describing a more-than-20% selloff show that investors are prioritizing near- to medium-term uncertainty over the positive durability results. Why Nektar Shares Fell Despite Promising Alopecia Results